The result is maximized retention of stem cells to repair the heart. The findings appear in the journal Circulation: Cardiovascular Interventions.
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
“Although biotherapies are increasingly more sophisticated, the tools for delivering regenerative therapies demonstrate a limited capacity in achieving high cell retention in the heart,” says Atta Behfar, M.D., Ph.D., a Mayo Clinic cardiology specialist and lead author of the study. “Retention of cells is, of course, crucial to an effective, practical therapy.”
Researchers from the Mayo Clinic Center for Regenerative Medicine in Rochester and Cardio3 Biosciences in Mont-Saint-Guibert, Belgium, collaborated to develop the device, beginning with computer modeling in Belgium. Once refined, the computer-based models were tested in North America for safety and retention efficiency.
What’s the significance?
- The new curved catheter eliminates backflow and limits loss of cells
- Graded small to large side holes limit pressures in the heart to keep cells targeted
- The design has proved to be more effective in both healthy and damaged hearts
This new catheter is being used in the European CHART-1 clinical trials, now underway. This is the first Phase III trial to regenerate hearts of patients who have suffered heart attack damage. The studies are the outcome of years of basic science research at Mayo Clinic and earlier clinical studies with Cardio3 BioSciences and Cardiovascular Centre in Aalst, Belgium, conducted between 2009 and 2010.
The development of the catheter and subsequent studies were supported by Cardio3 BioSciences; Walloon Region General Directorate for Economy, Employment & Research; Meijer Lavino Foundation for Cardiac Research Aalst (Belgium); the National Institutes of Health; Grainger Foundation; Florida Heart Research Institute; Marriott Heart Disease Research Program; and the Mayo Clinic Center for Regenerative Medicine.
Co-authors include Ruben Crespo-Diaz, Ph.D., Paul Stalboerger, Margaret Redfield, M.D., and Andre Terzic, M.D., Ph.D., all of Mayo Clinic; Jean-Pierre Latere, Ph.D., Christian Homsy, M.D., Dorothee Daro, Valerie Steenwinckel, Aymeric Seron, all of Cardio3 Biosciences; and Jozef Bartunek, M.D., Ph.D., of OLV Ziekenhuis. Mayo Clinic has a financial interest in the company referenced in this news release.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life.